-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansa Biopharma names Shannon Campbell, Gregory Perry to board

PUBT·09/24/2026 05:00:55
Listen to the news
Hansa Biopharma names Shannon Campbell, Gregory Perry to board
  • Hansa Biopharma elected Shannon Campbell and Gregory Perry to its board effective Sept. 22, 2026, serving until the next AGM.
  • Campbell is EVP and chief commercial officer at Merus, leading global commercialization through its acquisition by Genmab.
  • Perry is CFO at Merus, leading financings and strategic development through the Genmab acquisition; previously CFO at Finch Therapeutics, Novelion Therapeutics.
  • Michael Bologna, chief investment officer at NovaQuest Capital Management, stepped down from the board.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260923:BIT:4495:0) on September 24, 2026, and is solely responsible for the information contained therein.